We identified intratumor heterogeneity of the CDKN2A/B deletion in one of the two IDH-mutant astrocytomas, CNS WHO grade 4 in our cohort after excluding samples with low tumor purity. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).